Emerging company roundup: Kintai, Nocion, Arrakis and more
In a busy week for Boston-area biotechs, at least two companies debuted -- microbiome-mimicking small molecule company Kintai and pain play Nocion -- while a third, Arrakis, raised a $75 million series B round.
Kintai Therapeutics Inc. (Cambridge, Mass.), Flagship Pioneering’s latest foray into microbiome-based medicines, emerged from stealth mode Tuesday to develop oral small molecules that mimic microbes’ therapeutic effects. The company, whose financing is not disclosed, is led by CEO Paul-Peter Tak (see “Kintai’s Host-targeting Niche in Flagship Microbiome Ecosystem”). ...